Calquence – Display Banners Conference – 23464
ASCO A Focus On Leukemia eBook
ASCO Leukemia 2022.indd
High Mortality Risk in Patients With Leukemia Hospitalized With CDI
Among patients with leukemia admitted to the hospital with Clostridioides difficile infection...
Various Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall...
Various Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall survival (OS) compared with White patients, according to study results presented by Talha Badar, MBBS, MD, at the 2022 American...
Acalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
OS benefit seen in 5-year data on ELEVATE-TN trial in CLL
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
ASCO Voices Event
This year ASCO Voices will be held on Saturday, June 4, from 12:00 PM – 1:00 PM CDT, at the Arie Crown Theater in McCormick Place Here are this year’s ASCO Voices: Cancer: Common Humanity, Different Worlds Kevin...
Continuing Education At ASCO 2022
Sessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Why To Attend ASCO 2022
Join more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
CLL: Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil
Researchers previously demonstrated improved efficacy of acalabrutinib (A) obinutuzumab (O) vs. O...
R/R CLL: Acalabrutinib Vs Rituximab With Idelalisib or Bendamustine
Acalabrutinib (Acala) was a next-generation, highly selective, covalent Bruton tyrosine kinase...
